Tyrosine kinase inhibitorPhase 3 trialInvestigational
Selpercatinib
How it works
Blocks the RET, NTRK, and ROS1 kinases on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— RET-mutated, ROS1-mutated, ALK-positive
Efficacy
Clinical trials have shown that selpercatinib can improve overall survival in patients with RET-mutated, NTRK-fused, or ROS1-mutated non-small cell lung cancer, with some patients experiencing complete or partial responses.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Norwegian Study Explores Earlier Reimbursement Decisions for Lung Cancer Treatment | Lung Cancer | phase-2 | — | Source → |
| Selpercatinib Improves Event-Free Survival in Rare Lung Cancer | Lung Cancer | phase-3 | The study found a substantial improvement in event-free survival. | Source → |
| Selpercatinib Helps Prevent Cancer Return in Early-Stage Lung Cancer | Lung Cancer | phase-3 | Two-year investigator-assessed event-free survival was 92% with selpercatinib and 61% with placebo. | Source → |
| Managing Side Effects of New Cancer Treatment | Lung Cancer | review | — | Source → |
| Rare Cancer Mutation Responds to Selpercatinib Treatment | Colorectal Cancer | observational | — | Source → |
| Targeted Therapy and Surgery for Rare Lung Cancer | Lung Cancer | observational | — | Source → |
| Patient Resists Treatment with RET Inhibitor for Pancreatic Cancer | Pancreatic Cancer | observational | — | Source → |
| Selpercatinib May Cause Severe Hypersensitivity in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| New Study Compares Selpercatinib to Chemotherapy in Lung Cancer Patients | Lung Cancer | phase-3 | The median progression-free survival was 24.8 months with selpercatinib and 11.2 months with control treatment. | Source → |
| New Treatment Option for Lung Cancer Patients with Specific Genetic Mutation | Lung Cancer | phase-1/2 | Selpercatinib treatment was associated with robust and durable responses, including intracranial responses. | Source → |
| New Treatment for Lung and Thyroid Cancers with RET Gene Mutations | Lung Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.